Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience

Table 1 Baseline demographics and patient characteristics

Parameter	Overall, n = 177	Genotype 1					Genotype 2 SOF/RBV n = 42
		IFN/TVR/RBV n = 5	IFN/SMV/RBV n = 11	DCV/ASV n = 43	LDV/SOF n = 66	OBV/PTV/r n = 10
Age, median1	67.8 (11.0)	62.9 (8.7)	60.2 (8.9)	72.7 (8.3)	66.0 (11.2)	70.9 (6.5)	67.5 (12.6)
> 65, n (%)	118 (66.7)	3 (60)	4 (36.4)	37 (88.1)	39 (59.0)	7 (70)	29 (67.4)
Sex, n (%)
Male	79 (44.6)	3 (60)	7 (63.6)	14 (32.6)	31 (47.0)	4 (40)	20 (47.6)
Female	98 (55.4)	2 (40)	4 (36.4)	29 (67.4)	35 (53.0)	6 (60)	22 (52.4)
HCV RNA, median Log10 LGE1	6.1 (0.8)	6.5 (0.56)	6.2 (1.1)	6.30 (0.5)	6.16 (0.6)	5.4 (0.9)	5.8 (0.9)
> 100000 IU/mL, n (%)	109 (61.6)	4 (80)	9 (81.8)	32 (76.2)	43 (0.7)	2 (20)	19 (45.2)
Cirrhosis present, n (%)
Yes	74 (41.8)	0 (0)	0 (0)	34 (79.0)	29 (44.0)	3 (30)	8 (18.6)
No	103 (58.2)	5 (100)	11 (100)	9 (20.1)	37 (56.0)	7 (70)	34 (81.4)
HCV treatment history, n (%)
Naïve	132 (74.6)	1 (20)	2 (18.2)	25 (58.1)	63 (95.5)	9 (90)	32 (76.2)
Prior IFN-based treatment	45 (25.4)	4 (80)	9 (81.8)	18 (41.8)	3 (4.5)	1 (1)	10 (23.8)
History of HCC, n (%)
Yes	26 (14.7)	1 (20)	0 (0)	19 (44.1)	3 (4.5)	0 (0)	3 (9)
No	151 (85.3)	4 (80)	11 (100)	24 (55.8)	63 (95.5)	10 (100)	39 (90.7)
Laboratory values
Baseline platelet count, mean (× 104/μL)1	15.1 (6.5)	15.4 (3.4)	15.1 (6.2)	11.5 (5.8)	15.5 (6.5)	18.0 (5.96)	17.6 (6.0)
Baseline ALT level, mean (IU/L)1	51.2 (37.3)	41.8 (9.7)	50.1 (50.5)	53.1 (27.8)	60.3 (45.2)	39.9 (26.8)	38.9 (28.6)
Baseline AFP level, mean (ng/mL)1	12.1 (17.6)	5.6 (1.6)	7.18 (9.1)	23.4 (27.2)	8.99 (11.6)	9.9 (11.6)	6.8 (6.9)

¹The standard deviation is given in parentheses. AFP: Alpha fetoprotein; ALT: Alanine aminotransferase; DCV/ASV: Daclatasvir/asunaprevir; HCV: Hepatitis C virus; IFN: Interferon; LDV/SOF: Ledipasvir/sofosbuvir; OBV/PTV/r: Ombitasvir/paritaprevir/ritonavir; RBV: Ribavirin; SMV: Simeprevir; TVR: Telaprevir.